CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
Optisondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02440334
NCT02440334Phase 2Completed
CompareCT.gov

Two and Three Dimensional Contrast-Enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation

Thomas Jefferson University·interventional·Posted May 12, 2015·Updated May 4, 2025

In Brief

A Phase 2 clinical trial evaluating Optison for Renal Cell Carcinoma. Completed, enrolled 53 participants across 1 site.

Detailed Summary

The purpose of the proposed trial is to determine whether contrast-enhanced ultrasound (CEUS) can be used to assess the recurrence of renal cell carcinoma (RCC) after cryoablation compared to contrast enhanced CT or MR (the standard evaluation). This study involves the off-label use of an FDA-approved ultrasound contrast agent, Optison that flows in the vascularity. CEUS will be performed by both two and three dimensional ultrasound to examine post-cryoablation vascularity changes to screen for recurrent disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 12, 2015
Enrollment StartApr 23, 2015
Primary CompletionDec 1, 2017
Study CompletionJun 21, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.1 years ago

Interventions

Optisondrug

Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.